Compare · DFTX vs SNDL
DFTX vs SNDL
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and SNDL Inc. (SNDL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and SNDL operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $4.60B, about 15.5x SNDL ($297.8M).
- DFTX has been more active in the news (8 items in the past 4 weeks vs 7 for SNDL).
- DFTX has more recent analyst coverage (8 ratings vs 4 for SNDL).
- Company
- Definium Therapeutics Inc.
- SNDL Inc.
- Price
- -
- -
- Market cap
- $4.60B
- $297.8M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 8
- 7
- Recent ratings
- 8
- 4
SNDL
SNDL Inc.
Sundial Growers Inc. engages in production and marketing of cannabis products for the adult-use market in Canada. It produces and distributes inhalable products, such as flower, pre-rolls, and vapes. The company offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. Sundial Growers Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.
Latest DFTX
- Definium Therapeutics Announces New Employee Inducement Grants
- Analyst initiated coverage on Definium Therapeutics with a new price target
- Chief Medical Officer Karlin Daniel sold $396,894 worth of shares (10,853 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 792,846 units (SEC Form 4) (withholding obligation)
- Chief Executive Officer Barrow Robert sold $1,153,784 worth of shares (31,550 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 2,213,090 units (SEC Form 4) (for withholding tax)
- Chief Commercial Officer Wiley Matthew T. sold $113,257 worth of shares (3,097 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.86% to 359,036 units (SEC Form 4) (for tax liability)
- Chief Legal Officer Sullivan Mark sold $513,845 worth of shares (14,051 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 494,228 units (SEC Form 4) to satisfy withholding tax
- Chief Financial Officer Roberts Brandi sold $123,497 worth of shares (3,377 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.85% to 394,528 units (SEC Form 4) (withholding tax)
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form 144 filed by Definium Therapeutics Inc.
- SEC Form 144 filed by Definium Therapeutics Inc.
Latest SNDL
- SEC Form SC TO-C filed by SNDL Inc.
- SEC Form 6-K filed by SNDL Inc.
- SNDL Announces 2026 Annual and Special Shareholders Meeting Results, Select Preliminary Third Quarter Results and Capital Return Initiatives
- SEC Form 6-K filed by SNDL Inc.
- SNDL to Report Third Quarter 2026 Financial Results on October 27, 2026
- SEC Form 6-K filed by SNDL Inc.
- SNDL Announces Resignation of Director
- SEC Form 6-K filed by SNDL Inc.
- SEC Form 6-K filed by SNDL Inc.
- SNDL Announces Successful Completion of EU-GMP Audit at Atholville Facility